Sight Sciences (SGHT) CLO sells 6,308 shares to cover RSU taxes

Rhea-AI Filing Summary

Sight Sciences Chief Legal Officer Jeremy B. Hayden reported selling 6,308 shares of the company’s common stock on January 16, 2026 at a weighted average price of $6.62 per share. The shares were sold to cover his tax liability arising from the vesting of restricted stock units, rather than as a discretionary open-market sale. Following this transaction, he beneficially owns 267,611 shares, consisting of 75,562 shares of common stock and 192,049 shares that will be received upon vesting and settlement of unvested RSUs. The filing also clarifies prior reporting by adding 39,825 previously omitted RSU shares and removing 11,326 stock option shares that had been inadvertently included in an earlier balance.

Insider Trade Summary

Net Seller: 6,308 shares ($41,759)

Net Sell 1 txn

Insider HAYDEN JEREMY B.

Role Chief Legal Officer

Sold 6,308 shs ($42K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,308	$6.62	$42K

Holdings After Transaction: Common Stock — 267,611 shares (Direct)

Footnotes (1)

1. Reflects shares of the Issuer's common stock, par value $0.001 per share ("common stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Reflects the weighted average price at which the shares of common stock were sold. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes (i) 75,562 shares of common stock, and (ii) 192,049 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested. The Reporting Person previously reported a grant of 12,000 RSUs on a Form 4 filed on February 11, 2022 (which was subsequently included under Table 1 on a Form 4 filed on January 5, 2023) and a grant of 45,100 RSUs on a Form 4 filed on March 21, 2023, which were awarded on February 9, 2022 and March 16, 2023, respectively. Of these RSU grants, 39,825 shares were inadvertently excluded from the Reporting Person's beneficially owned shares. The reported balance includes these previously excluded shares. Furthermore, the Reporting Person's Form 4 filed on February 16, 2024 inadvertently included under Column 5 of Table I 11,326 shares of common stock underlying the Reporting Person's stock options that were to vest within 60 days of the date of such filing. The reported balance on this Form 4 excludes the number of shares underlying such stock options.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAYDEN JEREMY B.

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		S		6,308(1)	D	$6.62(2)	267,611(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of the Issuer's common stock, par value $0.001 per share ("common stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.

2. Reflects the weighted average price at which the shares of common stock were sold. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes (i) 75,562 shares of common stock, and (ii) 192,049 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested.

4. The Reporting Person previously reported a grant of 12,000 RSUs on a Form 4 filed on February 11, 2022 (which was subsequently included under Table 1 on a Form 4 filed on January 5, 2023) and a grant of 45,100 RSUs on a Form 4 filed on March 21, 2023, which were awarded on February 9, 2022 and March 16, 2023, respectively. Of these RSU grants, 39,825 shares were inadvertently excluded from the Reporting Person's beneficially owned shares. The reported balance includes these previously excluded shares. Furthermore, the Reporting Person's Form 4 filed on February 16, 2024 inadvertently included under Column 5 of Table I 11,326 shares of common stock underlying the Reporting Person's stock options that were to vest within 60 days of the date of such filing. The reported balance on this Form 4 excludes the number of shares underlying such stock options.

	/s/Jeremy Hayden	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SGHT’s Chief Legal Officer report?

Sight Sciences’ Chief Legal Officer, Jeremy B. Hayden, reported the sale of 6,308 shares of common stock on January 16, 2026, coded as a sale transaction.

At what price were the SGHT shares sold in this Form 4 filing?

The 6,308 shares of Sight Sciences common stock were sold at a weighted average price of $6.62 per share, with individual trades ranging from $6.44 to $6.69.

Why did Jeremy B. Hayden sell SGHT shares according to the filing?

The filing states that the shares were sold to cover the reporting person’s tax liability arising from the vesting of restricted stock units, not as a discretionary stock sale.

How many SGHT shares does the insider beneficially own after this transaction?

After the reported sale, Jeremy B. Hayden beneficially owns 267,611 shares of Sight Sciences common stock, including 75,562 shares of stock and 192,049 shares that will be acquired upon vesting and settlement of unvested RSUs.

Does this SGHT Form 4 correct any prior beneficial ownership reporting?

Yes. The filing explains that 39,825 RSU shares were previously omitted from his beneficially owned shares and are now included, and 11,326 shares underlying stock options were inadvertently included in a prior filing and are now excluded from the reported balance.

What is the role of the reporting person in SGHT?

The reporting person, Jeremy B. Hayden, is an officer of Sight Sciences, serving as the company’s Chief Legal Officer, and is not listed as a director or 10% owner in this filing.